CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces that results from three Phase 2 studies of ISIS 301012, including effects of ISIS 301012 in homozygous familial hypercholesterolemic (HoFH) patients, will be the subjects of three upcoming presentations at the of Cardiology (ACC), March 24-27 in New Orleans. Planned presentations include effects of ISIS 301012 in patients both as monotherapy and added to stable statin therapy. An overall summary of the Phase 2 program results for ISIS 301012 will be provided at the March 27 Analyst/Investor webcast presentation, along with a summary of Isis' development plan for ISIS 301012. ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.
Sunday, March 25, 2007 Session: 1206: Vascular Disease, Hypertension and Prevention -- V-cast Poster Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Hall H Presentation: 1206-278 Abstract: Statin-Like, Dose-Dependent Reductions in LDL-C and Apolipoprotein B With ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, in Subjects With Polygenic Hypercholesterolemia Monday, March 26, 2007 Session: 603: Common Challenges in Preventive Cardiology (7:00 - 8:30 a.m. CT) Track: ACC.Symposium Room: Auditorium B Presentation: 603-8 Time: 8:15 - 8:30 a.m. Speaker: Dr. Evan A. Stein Title: High Low-Density Lipoprotein Cholesterol on Three Drugs* *to include preliminary results of an ongoing study evaluating ISIS 301012 in HoFH patients on concurrent maximally tolerated lipid-lowering therapies Session: 820: Clinical Trials of Lipid-Lowering Therapy (4:00 - 5:30 p.m. CT) Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Auditorium B Presentation: 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein Cholesterol and Apolipoprotein B in Hypercholesterolemic Subjects on Statins Not Meeting Target Tuesday, March 27, 2007 Presentation: Isis Pharmaceuticals' Live Analyst/Investor Webcast Time: 7:00 a.m. CT Where: www.isispharm.com How: Live over the Internet -- select the link on Isis' home page at the address above.
If you are unable to participate during the live webcast, the presentation will be available for replay at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of ov er 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
This press release includes forward-looking statements regarding the development, therapeutic potential and safety of ISIS 301012 in treating high cholesterol and cardiovascular disease. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, which is on file with the SEC. Copies of this and other documents are available from the Company.
CONTACT: Kate Corcoran, Ph.D., Vice President, Corporate Development ofIsis Pharmaceuticals, +1- -760-603-2331
Web site: http://www.isispharm.com/
Ticker Symbol: (NASDAQ-NM S:ISIS)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company